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Tucson, Arizona
Amiodarone is known to raise serum digoxin levels. This
study was designed to evaluate the pharmacokinetic ba-
sis of this interaction in 10 normal subjects. The phar-
macokinetic variables for digoxin were determined after
a 1.0 mg intravenous dose of digoxin in each subject,
before and after oral amiodarone, 400 mg daily for 3
weeks. During amiodarone administration, systemic
clearance of digoxin was reduced from 234 ± 72 ml/min
(mean ± standard deviation) to 172 ± 33 ml/min (p <
0.01). This was due to reductions in both renal clearance
(from 105 ± 39 to 84 ± 15 ml/min) (p < 0.05) and
nonrenal clearance (from 130 ± 38 to 88 ± 20 ml/min)
Numerous drugs are known to alter the pharmacokinetic
behavior of digoxin. Amiodarone has been found to raise
serum digoxin concentrations (1-5); however, there is little
infomiation regarding the mechanism and clinical signifi-
cance of this interaction. This study was designed to evaluate
the pharmacokinetic nature of the digoxin-amiodarone
interaction.
Methods
Study subjects. Ten normal adult volunteers entered and
completed the study. After a thorough review ofthe possible
risks associated with amiodarone administration, the pro-
tocol was approved by the Human Subjects Committee of
the University of Arizona. Informed written consent was
obtained from each subject before enrollment. In addition,
permission to use amiodarone in normal human volunteers
was secured through an Investigational New Drug appli-
cation to the Food and Drug Administration. All subjects
were men aged 21 to 36 years. All had unremarkable med-
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(p < 0.01). Digoxin half-life of elimination was prolonged
from 34 ± 13 to 40 ± 16 hours (p < 0.05). Digoxirl
volume of distribution was not significantly changed.
Amiodarone caused a three- to fivefold increase in setum
reverse triiodothyronine levels, but changes in thyroid
function were not quantitatively related to the changes
in digoxin pharmacokinetics.
These alterations in digoxin pharmacokinetics
produced by amiodarone explain the increase in serum
digoxin level that has been observed when this drug
combination has been used clinically.
(J Am Coli CardioI1985;5:108-12)
ical histories, normal findings on physical examination, nor-
mal hemoglobin concentration andnormal thyroid, liver and
renal chemistry values. Thyroid studies included measure-
ment of total thyroxine, free thyroxine index, triiodothy-
ronine resin uptake, free triiodothyronine and reverse triio-
dothyronine. No subject was taking any medication at the
time of enrollment in the study.
Protocol. In each subject, the pharmacokinetic behavior
of digoxin after a single 1.0 mg intravenous dose was de-
termined twice. First, digoxin was administered alone; the
second digoxin dose was given after 3 weeks of oral amio-
darohe. Digoxin (Lanoxin) was given as an intravenous
infusioh into an arm vein over 10 minutes. Blood samples
were drawn from the contralateral arm at 15, 30, 45 and
60 minutes and at 2, 3. 4, 6, 8, 24, 32, 48, 56, 72, 80,
96, 104 and 120 hours after the dose. Serum was separated
and stored frozen at - 20DC until assayed. Complete 24
hour urine collections were obtained daily for 5 days after
the dose. Urine volumes were measured, and an aliquot was
stored frozen until assayed.
Subjects were then given oral amiodarone (Cordarone,
Labaz) , 400 mg daily. After 21 to 25 days of amiodarone
administration, the 1.0 mg intravenous digoxin dose was
repeated, and blood and urine samples were collected ac-
cording to the same schedule as after the first digoxin dose.
Amiodarone was continued for 5 days after this digoxin
dose. Amiodarone is known to produce hyper- or hypothy-
roidism. Alterations in thyroid function affect digoxin phar-
macokinetics. Therefore, during the fourth week of amio-
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darone administration. additional bloodsamples wereobtained
for measurement of free triiodothyronine, reverse triiodo-
thyronine, total thyroxine and free thyroxine index.
Analytical methods. Digoxin serum and urine concen-
trations were determined in all samples by radioimmu-
noassay with a solid phase technique (Clinical Assay. Trav-
enol). The coefficient of variation for this assay was 5.2%
at 0,75 ng/ml, 4.7% at 1.4 ng/ml and 4,5% at 3.8 ng/m\.
With this assay. serum concentrations of digoxin were re-
liably measured to a minimum of 0,15 ng/m\. Serum sam-
ples from each subjectcontaining amiodaronebut no digoxin
were assayed for digoxin, In no case did the assay falsely
detect digoxin in these samples.
Total thyroxine determinations were performed by a com-
petitive binding radioimmunoassay method (GAMMA-
COAT, Clinical Assays, Cambridge). Triiodothyronine resin
uptake was measured by the inorganic adsorbent method
(TRITAB. Nuclear Medical Laboratories). Free thyroxine
index is a mathematical calculation, which is the product
of total thyroxine and triiodothyronine resin uptake divided
by the mean normal triiodothyronineresin uptake. Free triio-
dothyronine determinations were made by dialysis, utilizing
incubation at 37° for 16 to 18 hours. and subsequent mea-
surement by radioimmunoassay (Nichols Institute). Reverse
triiodothyroninewas measured by the PEG method utilizing
radioimmunoassay technique and competitive inhibition with
antibody produced in rabbits (Serono Laboratories. Inc.).
Serum and urine samples were assayed for creatinine by
a modification of the Technicon Autoanalyzer adaptation of
the method of Folin and Wu (6).
Data analysis. For each digoxin injection in each sub-
ject, digoxin serum concentration versus time data were
individually fit to a multiexponential equation by means of
a nonlinear regression computer program. All data were fit
to two or three exponential terms, The most appropriate
equation was determined using a statistical test of signifi-
cance (7),
The pharmacokinetic variables of half-life, systemic
clearance. apparent volume of distribution and area under
the serum concentration versus time curve were calculated
from the coefficientsand exponents of the fittedcurves using
standard methods (8), Renal clearance of digoxin was cal-
culated by dividing the amount eliminated in the urine during
the 5 days after intravenous injection by the area under the
curve for the same period, Digoxin nonrenal clearance was
calculated as the difference between systemic clearance and
renal clearance.
Creatinine clearances were calculated by dividing the
amount eliminated in the urine in 24 hours by the serum
concentration at the midpoint of the collection period,
Statistical methods. Statistical comparisons of the phar-
macokineticvariablesof digoxin in the absence and presence
of amiodarone were made using Student's paired t test.
Results
Digoxin pharmacokinetics afteramiodarone. Table I
summarizes the pharmacokinetic values obtained in each
subject after each digoxin injection, Figure 1shows the time
course of digoxin serum concentrations after intravenous
administration alone, and then with concurrent oral amio-
darone administration in one subject. In the presence of
amiodarone, systemic clearance of digoxin in the 10subjects
was reduced 26%, from 234 ± 72 milmin (mean ± standard
deviation) to 172 ± 33 mllmin (p < 0.01). Only two sub-
jects (Cases 8 and 10) failed to show a substantial reduction
in digoxin systemic clearance, After the addition of amio-
darone, digoxin renal clearance was reduced 20%, from
Table 1. Pharmacokinetic Variables for Digoxin Alone and in the Presence of Amiodarone in 10 Normal Subjects
Systemic Nonrenal Volume of
Clearance Renal Clearance Clearance Distribution Elimination
(ml/min l (ml/rnin) (rnl/minl (liters/kg) Half-Life (hours)
Case D D+A D D+A D D+A D D+A D D+A
256 189 118 93 138 96 7.1 8.8 21 36
2 374 206 193 106 181 100 10.4 6.6 21 24
3 253 128 114 59 139 69 12.4 7.1 38 44
4 241 200 99 91 142 109 7.1 5.5 23 22
5 322 211 127 92 195 119 9.0 6.8 22 25
6 213 191 96 96 1\7 95 15.6 18.7 58 77
7 189 149 61 71 128 78 9.9 9.4 39 47
8 137 137 55 71 82 66 6.2 5.9 35 33
9 190 126 101 70 89 56 12.0 7.4 51 47
10 167 181 81 88 86 93 7.5 9.4 35 41
Mean 234 172 105 84 130 88 9.7 8.6 34 40
±SD 72 33 39 15 38 20 3.0 3.8 13 16
P <0.01 <0.05 <0.01 NS <0.05
D = digoxin alone; D + A = digoxin with concurrent amiodarone.
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Figure 1. Semilogarithmic plot of the serum concen-
tration of digoxin as a function of time after the intra-
venous administration of digoxin alone (.) and during
concurrent amiodarone treatment (0) in one subject.
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105 ± 39 to 84 ± 15 ml/min (p < 0.05). In four of the
subjects, however, there was either no change or a slight
increase in digoxin renal clearance. Amiodarone produced
a 32% reduction in digoxin nonrenal clearance, from 130
± 38 to 88 ± 20 mllmin (p < 0.01). The reduction in
digoxin nonrenal clearance was observed in 9 of the 10
subjects. Digoxin elimination half-life was prolonged after
amiodarone in seven subjects. For the whole group, the
prolongation from 34 to 40 hours was statistically significant
(p < 0.05). The mean digoxin volume of distribution was
not significantly altered by amiodarone administration.
Creatinine clearance was measured on the first and fifth
days after each digoxin dose. There was no significantchange
in creatinine clearance either within or between treatment
periods. For the group, the mean creatinine clearance was
112 ± 19 mllmin after the first digoxin dose and 113 ±
18 mllmin after the second digoxin dose.
Thyroid function after amiodarone. Table 2 summa-
rizes the thyroid function data obtained in each subject be-
fore and after 3 weeks of amiodarone therapy. Despite the
low dose of amiodarone, each subject had a substantial
increase in serum reverse triiodothyronine levels. The serum
Table 2. Thyroid Function Before and After 3 Weeks of Amiodarone in 10 Normal Subjects
Reverse Free
Triiodothy- Triiodothy- Total Free
ronine* roninet Thyroxinej Thyroxine
(pg/ml) (pg/dl) (ll-g%l100 ml) Index§
Case C A C A C A C A
I 244 638 339 194 8.6 5.3 8.0 7.4
2 85 246 292 226 7.0 7.7 7.1 8.1
3 127 532 317 239 8.3 8.0 9.6 8.6
4 159 459 275 222 6.6 7.4 8.0 8.3
5 100 573 270 193 5.7 6.5 6.4 9.5
6 125 429 271 241 8.0 8.6 7.8 7.8
7 102 417 246 195 7.2 7.6 8.2 6.9
8 99 392 274 159 7.0 6.8 9.0 6.8
9 227 711 238 293 7.8 6.7 8.6 7.4
10 121 561 346 294 8.9 7.4 8.3 9.3
Mean 139 496 287 226 7.5 7.2 8.1 8.0
±SD 55 135 37 44 0.9 0.9 0.9 0.9
P <0.001 <0.001 NS NS
*Normal range 80 to 350 pg/ml; t normal range 230 to 660 pg/dl; :j:normal range 4.5 to 11.5 Il-g%/IOO ml;
§ normal range 3.75 to 13.4. A = after3 weeks of amiodarone; C = control, before amiodarone.
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concentration of free triiodothyronine decreased in eight
subjects , and fell below normal values in six of these eight.
We found no consistent changes in total thyroxine or free
thyroxine index. No subject developed any clinical mani-
festation of abnormal thyroid function.
No subject experienced any significant adverse reaction
to either digoxin or amiodarone .
Discussion
Previous study. Several reports document a rise in serum
digoxin concentration when amiodarone is added to long-
term oral digoxin therapy . Moysey et al. (I) noted an av-
erage increase of 69% in plasma digoxin concentrations
when amiodarone, 600 mg daily, was added to long-term
digoxin treatment in seven patients . Four patients developed
symptoms compatible with digoxin toxicity . In two addi-
tional patients, plasma digoxin concentrations increased after
maintenance amiodarone was increased from 200 to 600 mg
daily. Furlanello et al. (2) found a linear correlation between
plasma amiodarone levels and plasma digoxin or beta-
methyldigoxin levels in 33 patients on long-term treatment
with both drugs. None of their patients developed toxic
plasma digoxin levels or signs of digitalis toxicity.
Nademanee et al. (3) found that amiodarone , 600 to
1,800 mg daily for at least 2 weeks , increased plasma di-
goxin levels in all 20 patients studied on long-term treatment
with both drug s. During combination treatment, two patients
developed sinus arrest, seven had gastrointestinal side ef-
fects and five had neurotoxicity . Similarly, Oetgen et al.
(4) reported an increase in serum digoxin levels in 22 pa-
tients, from 1.0 ± 0.4 ng/ml before amiodarone to 1.9 ±
0.8 ng/ml after 7 weeks on amiodarone . In contrast, Achilli
er al. (5) found no effect of amiodaronc, 200 mg twice
daily, on digoxin serum concentrations in five patients treated
with this combination .
Pharmacokinetic basis of interaction. We have inves-
tigated the pharmacokinetic basis of this interaction . Arnio-
darone raises serum digoxin levels by reducing digoxin sys-
temic clearance . This is due to reduction in both the renal
and nonrenal clearances of digoxin. Digoxin volume of dis-
tribution is essentially unchanged. The observed prolon-
gation of digoxin elimination half-life is the necessary con-
sequence of the reduction in digoxin systemic clearance in
the absence of a change in volume of distribution.
In the absence of changes in bioavailability and volume
of distribution, a 26% reduction in clearance should produce
approximately a 33% increa se in mean steady state digoxin
levels. Previou s investigators (1 ,3,4) reported even greater
percent increases in digoxin trough levels after the addition
of amiodarone . This may indicate that the magnitude of the
interaction is dependent on the dose or serum concentration
of amiodarone . In the reports of Nademanee and Moyscy
and their coworkers (1,3), the daily dose of amiodarone was
at least 600 mg, compared with 400 mg in this study . Fur-
thermore, these clinical reports are based on findings in
patients receiving long-term oral digoxin therapy. The ef-
fects of amiodarone on digoxin pharmacokinetics may be
enhanced in patients with reduced cardiac output or impaired
renal funct ion compared with normal volunteers. It is also
possible that amiodarone increases the absorption of orally
administered digoxin. We observed considerable interin-
dividual variation in the magnitude of the amiodarone effect
on digoxin pharmacokinetics. This could possibly be due
to the interindividual variability in amiodarone pharmaco-
kinetic s, but we do not have amiodarone serum levels avail-
able for comparison in our subjects.
The digoxin-amiodarone interaction is complex. The de-
crease in digoxin renal clearance is not due to a change in
glomerular filtration rate , since creatinine clearance did not
change . However, digoxin is also eliminated by tubular
secretion (9), and amiodarone, like quinidine (10) and spi-
ronolactone (9) , may affect this process . Amiodarone also
reduce s digoxin nonrenal clearance. This probably indicates
a decrease in digoxin excretion or biotransformation in either
the liver or the gut.
Role of changes in thyroid function. Any of these ef-
fects of amiodarone may be due to a direct action of the
drug or may be mediated in part by an alteration in thyroid
function . Digoxin metabolism and elimination are altered
in clinical hypo- and hyperthyroidism (11) . Amiodarone
inhibits peripheral deiodination of thyroxine to triiodothy-
ronine, resulting in increa sed production of reverse triio-
doth yronine . The changes in thyroid chemistry values ob-
served in our subjects are in agreement with those reported
by Burger et al. (12) in normal volunteers receiving the
same dose of amiodarone. Although we found substantial
increases in reverse triiodothyronine levels and decreases in
free triiodothyronine levels with amiodarone , no patient had
any clinic al manifestation of altered thyroid function . We
found no consistent relation between the magnitude of change
in rever se triiodothyronine level. or any other variable of
thyroid function , and the magnitude of change in any of the
pharmacokinetic variables. The antiarrhythmic and electro-
physiologic effects of amiodarone have been predicted from
reverse triiodothyronine levels (13) . The effect of amio-
darone on digoxin pharmacokinetics does not appear to be
quantitatively related to changes in thyroid chemistry values.
Conclusions. Amiodarone reduce s digoxin renal and
nonrenal clearances and prolongs digoxin elimination half-
life . The clinical consequences of this interaction are not
fully defined at present. However, to reduce the risk of
digitalis toxicity . we recommend that serum digoxin level s
be monitored after initiation of amiodarone therapy . Our
data indicate that to maintain a stable serum digoxin con-
centration, the dose of digoxin should be decreased by ap-
proximately one-fourth after initiating amiodarone.
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